FTO and acute myeloid leukemia: Likewise, the half-life of IGFBP2 mRNA transcripts manifested a dose-dependent reduction when the two t(8;21) AML cells were treated with FB23-2 (Fig. 6L), suggesting that upregulation of IGFPB2 is at least partially attributed to the increased stability of its transcripts mediated by FTO-induced m6A demethylation.